FDA 510(k) for IVD — Signal or Noise?

What Is a 510(k) Clearance?

The FDA 510(k) is the most common clearance pathway for medical devices in the US. The manufacturer must demonstrate that its product is "substantially equivalent" to an already cleared product (Predicate Device) — essentially the same in intended use, technology, and safety.

For IVD manufacturers, the 510(k) is the standard gateway to the US market. In the first six months of 2026, the FDA published over 1,200 510(k) clearances for IVD products — from SARS-CoV-2 tests to genetic assays to clinical chemistry analyses.

Why Every 510(k) Is a Business Signal

Each of these clearances tells a story:

• Who received clearance? — A new competitor enters the market
• Which product? — A new technology category emerges
• Which predicate device? — Who is the established player against which it was compared
• When? — Temporal patterns reveal market dynamics

For a CDMO (Contract Development & Manufacturing Organization), every 510(k) clearance by an IVD manufacturer is a potential lead: the manufacturer needs production capacity, reagents, packaging, or logistics. Identifying the right manufacturers early significantly shortens the sales cycle.

Case Study: SARS-CoV-2 Test Clearance

In January 2026, a mid-sized IVD manufacturer received a 510(k) clearance for a rapid antigen test. The signal: the company had moved from development into production. The follow-on need: reagent sourcing, scale-up partners, distribution partners in the EU.

A CDMO that detected this signal in real time was able to submit a proposal within two weeks — and won the contract against four competitors who only learned of the market movement three months later.

From Noise to Signal — The Problem

The problem: hundreds of FDA clearances appear every day. Most are irrelevant for any given company. Manual screening fails due to sheer volume — and above all because a signal's relevance depends on the company's own technology profile.

A manufacturer of latex particle reagents needs a completely different filter than a provider of PCR thermocyclers.

Regulatory Signal Intelligence solves this problem through semantic matching: instead of rigid keyword filters ("COVID" OR "SARS"), a company's entire technology profile (products, technologies, target markets, patents) is matched against incoming signals. The system learns what is relevant — and prioritizes accordingly.

Automated Signal Monitoring with CI

Contextual Intelligence captures FDA clearances (510(k), PMA, De Novo) from the FDA database daily, enriches them with product descriptions, technology classes, and manufacturer information, and matches them against CI users' technology profiles.

The result: instead of manual FDA database screening, users receive only the signals that are truly relevant to their business — prioritized by HOT / WARM / COLD, with direct reference to their own product portfolio.